Stay updated on Cabozantinib vs Placebo in Radioiodine-Refractory Thyroid Cancer Clinical Trial
Sign up to get notified when there's something new on the Cabozantinib vs Placebo in Radioiodine-Refractory Thyroid Cancer Clinical Trial page.

Latest updates to the Cabozantinib vs Placebo in Radioiodine-Refractory Thyroid Cancer Clinical Trial page
- Check2 days agoChange DetectedAdded Padova, Italy, 35128 and removed Padua, Italy, 35128 from the list of study locations.SummaryDifference0.0%

- Check9 days agoChange DetectedAdded the term Differentiated thyroid carcinoma and a Resources section linking the Genetic and Rare Diseases Information Center.SummaryDifference0.1%

- Check16 days agoChange DetectedAdded Naples, Italy, 80131 as a study location and removed Napoli, Italy, 80131. The page revision was updated to v3.5.0.SummaryDifference0.1%

- Check24 days agoNo Change Detected
- Check31 days agoChange DetectedAdded revision entry v3.4.3 and removed revision v3.4.2 from the site's revision history.SummaryDifference0.0%

- Check59 days agoChange DetectedRevision: v3.4.2 was added. The government funding status notice and Revision: v3.4.1 were removed.SummaryDifference0.2%

- Check66 days agoChange DetectedA government funding lapse notice was added, noting that the NIH Clinical Center is open and status updates can be found at opm.gov. The page was updated to revision v3.4.1, replacing the prior v3.4.0.SummaryDifference0.2%

Stay in the know with updates to Cabozantinib vs Placebo in Radioiodine-Refractory Thyroid Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantinib vs Placebo in Radioiodine-Refractory Thyroid Cancer Clinical Trial page.